FDA 483 - ABO Plasma Glassboro LLC - March 14, 2023

An FDA inspection of ABO Plasma Glassboro LLC, a plasmapheresis center, revealed a significant failure in donor notification procedures. The firm did not make reasonable attempts to notify deferred donors within the required 8-week period, specifically for HCV reactive donors. This indicates a serious lapse in donor safety and regulatory compliance.